Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00894504. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer
Study identification
- NCT ID
- NCT00894504
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Gemcitabine Drug
- Panitumumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2010
- Primary completion
- Aug 31, 2014
- Completion
- Aug 31, 2014
- Last update posted
- May 14, 2015
2010 – 2014
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Robles | Thousand Oaks | California | 91360 | — |
| Aventura Hospital and Medical Center | Aventura | Florida | 33180 | — |
| Florida Cancer Specialists | Fort Myers | Florida | — | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| National Capital Clinical Research Consortium | Bethesda | Maryland | 20817 | — |
| St. Louis Cancer Care | Chesterfield | Missouri | 63017 | — |
| Research Medical Center | Kansas City | Missouri | 64132 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Family Cancer Center | Collierville | Tennessee | 38119 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Health Physician Group | Dallas | Texas | 76011 | — |
| Peninsula Cancer Institute | Newport News | Virginia | 23601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00894504, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2015 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00894504 live on ClinicalTrials.gov.